Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT02785952

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)

Sponsor: National Cancer Institute (NCI)

Conditions Recurrent Squamous Cell Lung Carcinoma Stage IV Squamous Cell Lung Carcinoma AJCC v7

Interventions Ipilimumab Laboratory Biomarker Analysis Nivolumab Quality-of-Life Assessment Questionnaire Administration

Updated 18 times since 2017 Last updated: May 12, 2025 Started: Dec 29, 2015 Primary completion: Dec 19, 2019 Completion: Apr 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02785952, this PHASE3 trial focuses on Recurrent Squamous Cell Lung Carcinoma and Stage IV Squamous Cell Lung Carcinoma AJCC v7 and remains ongoing. Sponsored by National Cancer Institute (NCI), it has been updated 18 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

18 versions recorded

Sep 2025 — Present [monthly]

Active Not Recruiting PHASE3
Jun 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE3
Sep 2024 — Jun 2025 [monthly]

Active Not Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE3

▶ Show 13 earlier versions

May 2023 — Jun 2024 [monthly]

Active Not Recruiting PHASE3
Jun 2022 — May 2023 [monthly]

Active Not Recruiting PHASE3
Feb 2022 — Jun 2022 [monthly]

Active Not Recruiting PHASE3
Jan 2021 — Feb 2022 [monthly]

Active Not Recruiting PHASE3
Oct 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE3
Oct 2019 — Oct 2020 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Sep 2018 — Oct 2019 [monthly]

Recruiting PHASE3
Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE3
Dec 2017 — Jun 2018 [monthly]

Recruiting PHASE3
Aug 2017 — Dec 2017 [monthly]

Recruiting PHASE3
Mar 2017 — Aug 2017 [monthly]

Recruiting PHASE3
Feb 2017 — Mar 2017 [monthly]

Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
SWOG Cancer Research Network

Data source: SWOG Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United States , Albany, United States , Albuquerque, United States , Allentown, United States , Amarillo, United States , American Fork, United States , Ames, United States , Anaconda, United States , Anacortes, United States , Anaheim, United States and 677 more locations